Journal article
A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (types 6/11/16/18) vaccine against high-grade cervical and external genital lesions
SK Kjaer, K Sigurdsson, OE Iversen, M Hernandez-Avila, CM Wheeler, G Perez, DR Brown, LA Koutsky, HT Eng, P García, KA Ault, SM Garland, S Leodolter, SE Olsson, GWK Tang, DG Ferris, J Paavonen, M Lehtinen, M Steben, FX Bosch Show all
Cancer Prevention Research | AMER ASSOC CANCER RESEARCH | Published : 2009
Abstract
Quadrivalent human papillomavirus (HPV) vaccine has been shown to provide protection from HPV 6/11/16/18-related cervical, vaginal, and vulvar disease through 3 years. We provide an update on the efficacy of the quadrivalent HPV vaccine against high-grade cervical, vaginal, and vulvar lesions based on end-of-study data from three clinical trials. Additionally, we stratify vaccine efficacy by several baseline characteristics, including age, smoking status, and Papanicolaou (Pap) test results. A total of 18,174 females ages 16 to 26 years were randomized and allocated into one of three clinical trials (protocols 007, 013, and 015). Vaccine or placebo was given at baseline, month 2, and month 6..
View full abstractGrants
Funding Acknowledgements
Grant support: Merck Research Laboratories, a Division of Merck & Company, Inc.